| 1 |
Comparison of Innovator vs. Biosimilar Ranibizumab in Treating Diabetic Macular Edema: A Multicenter Retrospective Study |
|
|
| Debdulal Chakraborty, Sabyasachi Sengupta, Soumen Mondal, Subhendu Boral, Arnab Das, Tushar Kanti Sinha, Ranabir Bhattacharya, Ritobroto Maitra |
|
| Ophthalmology and Therapy. 2022; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Future of anti-VEGF: biosimilars and biobetters |
|
|
| Monika Kapur, Suvansh Nirula, Mayuresh P. Naik |
|
| International Journal of Retina and Vitreous. 2022; 8(1) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Comments on: Clinical effectiveness and safety of razumab (A biosimilar of ranibizumab) |
|
|
| Mithun Thulasidas |
|
| TNOA Journal of Ophthalmic Science and Research. 2022; 60(1): 133 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World’s First Biosimilar Ranibizumab): A Comprehensive Review |
|
|
| Shashikant Sharma,Tanishq Sharma,Somdutt Prasad,Mahesh Gopalakrishnan,Alok Chaturvedi |
|
| Ophthalmology and Therapy. 2021; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study |
|
|
| Shashikant Sharma,Vishali Gupta,Aniruddha Maiti,Sribhargava Natesh,Sandeep Saxena,Vivek Dave,Vimal Parmar,Raju Sampangi,Hemanth Murthy,Sandhya Dharwadkar,Naresh Kumar Yadav,Shrinivas Joshi,Rahul Mayor,Dhanashree Ratra,Soumyava Basu,Neha Goel,Alok Chaturvedi,Ronak Patel,Vinu Jose |
|
| International Journal of Retina and Vitreous. 2021; 7(1) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
To study early and late effect of intravitreal injection Ranibizumab on Cystoid Macular Edema(CME) due to Branch Retinal Vein Occlusion (BRVO) |
|
|
| Anil Kumar, Ram Yash Singh Yadav, Ram Kumar, Ashutosh Kumar Singh, Chiranjee Rai |
|
| Indian Journal of Clinical and Experimental Ophthalmology. 2021; 7(1): 194 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
A comparative study between ranibizumab and its first biosimilar razumab in terms of efficacy and safety in DME, RVO and wet AMD associated with CNVM |
|
|
| Alok Preethi B,Alok Shilpa G,Dhwani Anil Shah,Praveen R Murthy |
|
| Indian Journal of Clinical and Experimental Ophthalmology. 2021; 7(2): 346 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 8 |
Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the worldæs first biosimilar Ranibizumab |
|
|
| Lalit Verma,Mithun Thulasidas,Ajay Purohit,Avnindra Gupta,Ritesh Narula,Dinesh Talwar |
|
| Indian Journal of Ophthalmology. 2021; 69(2): 347 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 9 |
A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (Worldæs First Biosimilar Ranibizumab) in Retinal Vein Occlusion |
|
|
| Shashikant Sharma,Mujtaba Khan,Alok Chaturvedi |
|
| Ophthalmology and Therapy. 2020; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 10 |
A Multicenter, Retrospective Study (RE-ENACT 2) on the Use of Razumab™ (World’s First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration |
|
|
| Shashikant Sharma,Mujtaba Khan,Alok Chaturvedi |
|
| Ophthalmology and Therapy. 2019; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 11 |
A Multinational Comparison of Anti-Vascular Endothelial Growth Factor Use: The United States, the United Kingdom, and Asia-Pacific |
|
|
| Ravi Parikh,Nathan Pirakitikulr,Jay Chhablani,Yoichi Sakurada,Rishi P. Singh,Yasha S. Modi |
|
| Ophthalmology Retina. 2018; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
